Tuesday, November 21, 2017
 
 
Company News: Page (1) of 1 - 10/13/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Medibio completes heavily oversubscribed institutional placement for $13.9 million to accelerate commercialisation

(October 13, 2017)

Highlights:

  • Placement completed, with oversubscriptions accepted up to $13.9 Million
  • Fidelity Investments follows on to maintain 10.6% ownership of the Company
  • IFM Investors and Regal FM to become substantial shareholders post-transaction
  • Medibio now fully funded to pursue aggressive commercialisation and IP strategy

SYDNEY, Australia and MINNEAPOLIS, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB)(OTCQB:MDBIF) is pleased to announce that it has received firm commitments to raise $13.9 million via the placement of 38,736,640 ordinary shares at a price of $0.36 per share.  The placement will be conducted in a single tranche using the Company’s existing placement capacity under ASX Listing Rule 7.1 and 7.1A.

The funds will allow the Company to:

  • Build out organisational infrastructure for product commercialisation
  • Establish requirements and testing of products and products under development for future market verticals
  • Development of technology platform and infrastructure, including engineering capability, to support commercialisation
  • Position Medibio for regulatory approvals on future products

Aesir Capital Pty Ltd acted as Sole Lead Manager to the transaction.  

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.   The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA.  Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcmarkets.com and www.asx.com.au.

Additional disclosure required by listing rule 3.10.5A

In accordance with listing rule 3.10.5A in relation to shares issued under the Company’s 7.1A capacity details of the placement are:

Effect of raisingThe effect of the announced raising on the capital structure of the Company is set out below.

 NumberDilution
Shares currently on issue156,196,558 
Placement  
Shares to be issued under LR7.1 placement capacity23,141,98414.82%
Shares to be issued under LR7.1A placement capacity15,594,6569.98%
Total Shares on issue after completion of the Placement194,933,19824.80%

The Company believes the benefits from funds raised in this placement at a discount to the 15-day VWAP of 11.9% outweigh the inability of shareholders to participate.  The placement was not underwritten and direct costs of the raising are up to 7.5% of funds raised.

CONTACT: Further Information: Website: www.medibio.com.auMedibio Shareholder Enquiries:Jack CosentinoCEO and Managing DirectorMedibio [email protected]: +1 (952) 465 4787Australian Media Enquiries:Peter TaylorNWR [email protected]: +61 (0) 412 036 231

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines